Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine

5-Azacitidine (AZA) is the standard-of-care agent for patients with high-risk myelodysplastic syndromes who are not candidates for high-dose chemotherapy [1, 2]. Toxicities related with AZA are mainly hematological, although gastrointestinal and dermatological adverse effects, such as exanthematic and neutrophilic reactions, can be observed [3]. In the elderly, there are difficulties in maintaining the dose intensities of AZA for prolonged periods of time [4]; for this reason, in our institution [...]